This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ma, C. X. Articles by Weinshilboum, R. M. Search for Related Content PubMed PubMed Citation Articles by Ma, C. X. Articles by Weinshilboum, R. M.

Human Aromatase: Gene Resequencing and Functional Genomics

Departments of ¹ Medical Oncology, ² Molecular Pharmacology and Experimental Therapeutics, ³ Biochemistry and Molecular Biology, and ⁴ Health Sciences Research, Mayo Clinic College of Medicine, Rochester, Minnesota

Requests for reprints: Richard M. Weinshilboum, Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic College of Medicine, 200 First Street, Southwest, Rochester, MN 55905. Phone: 507-284-2246; Fax: 507-284-9111; E-mail: weinshilboum.richard{at}mayo.edu.

Aromatase [cytochrome P450 19 (CYP19)] is a critical enzyme for estrogen biosynthesis, and aromatase inhibitors are of increasing importance in the treatment of breast cancer. We set out to identify and characterize genetic polymorphisms in the aromatase gene, CYP19, as a step toward pharmacogenomic studies of aromatase inhibitors. Specifically, we "resequenced" all coding exons, all upstream untranslated exons plus their presumed core promoter regions, all exon-intron splice junctions, and a portion of the 3'-untranslated region of CYP19 using 240 DNA samples from four ethnic groups. Eighty-eight polymorphisms were identified, resulting in 44 haplotypes. Functional genomic studies were done with the four nonsynonymous coding single nucleotide polymorphisms (cSNP) that we observed, two of which were novel. Those cSNPs altered the following amino acids: Trp³⁹Arg, Thr²⁰¹Met, Arg²⁶⁴Cys, and Met³⁶⁴Thr. The Cys²⁶⁴, Thr³⁶⁴, and double variant Arg³⁹Cys²⁶⁴ allozymes showed significant decreases in levels of activity and immunoreactive protein when compared with the wild-type (WT) enzyme after transient expression in COS-1 cells. A slight decrease in protein level was also observed for the Arg³⁹ allozyme, whereas Met²⁰¹ displayed no significant changes in either activity or protein level when compared with the WT enzyme. There was also a 4-fold increase in apparent K_m value for Thr³⁶⁴ with androstenedione as substrate. Of the recombinant allozymes, only the double mutant (Arg³⁹Cys²⁶⁴) displayed a significant change from the WT enzyme in inhibitor constant for the aromatase inhibitors exemestane and letrozole. These observations indicate that genetic variation in CYP19 might contribute to variation in the pathophysiology of estrogen-dependent disease.

This article has been cited by other articles:

				L. Wang, S. Kumar, B. L. Fridley, K. R. Kalari, I. Moon, L. L. Pelleymounter, M. A.T. Hildebrandt, A. Batzler, B. W. Eckloff, E. D. Wieben, et al. Proteasome {beta} Subunit Pharmacogenomics: Gene Resequencing and Functional Genomics Clin. Cancer Res., June 1, 2008; 14(11): 3503 - 3513. [Abstract] [Full Text] [PDF]

				I. Czajka-Oraniec, W. Zgliczynski, A. Kurylowicz, M. Mikula, and J. Ostrowski Association between gynecomastia and aromatase (CYP19) polymorphisms Eur. J. Endocrinol., May 1, 2008; 158(5): 721 - 727. [Abstract] [Full Text] [PDF]

				N. U. Lin and E. P. Winer Advances in Adjuvant Endocrine Therapy for Postmenopausal Women J. Clin. Oncol., February 10, 2008; 26(5): 798 - 805. [Abstract] [Full Text] [PDF]

				W. H. Xu, Q. Dai, Y. B. Xiang, J. R. Long, Z. X. Ruan, J. R. Cheng, W. Zheng, and X. O. Shu Interaction of Soy Food and Tea Consumption with CYP19A1 Genetic Polymorphisms in the Development of Endometrial Cancer Am. J. Epidemiol., December 15, 2007; 166(12): 1420 - 1430. [Abstract] [Full Text] [PDF]

				R. Ramirez-Lorca, A. Grilo, M. T. Martinez-Larrad, L. Manzano, F. J. Serrano-Hernando, F. J. Moron, V. Perez-Gonzalez, J. L. Gonzalez-Sanchez, J. Fresneda, R. Fernandez-Parrilla, et al. Sex and Body Mass Index Specific Regulation of Blood Pressure by CYP19A1 Gene Variants Hypertension, November 1, 2007; 50(5): 884 - 890. [Abstract] [Full Text] [PDF]

				T. A. Leil, C. Endo, A. A. Adjei, G. K. Dy, O. E. Salavaggione, J. R. Reid, M. M. Ames, and A. A. Adjei Identification and Characterization of Genetic Variation in the Folylpolyglutamate Synthase Gene Cancer Res., September 15, 2007; 67(18): 8772 - 8782. [Abstract] [Full Text] [PDF]

				N. U. Lin and E. P. Winer Optimal Use of Aromatase Inhibitors: To Lead or to Follow? J. Clin. Oncol., July 1, 2007; 25(19): 2639 - 2641. [Full Text] [PDF]

				M. H. Tao, Q. Cai, Z.-F. Zhang, W.-H. Xu, N. Kataoka, W. Wen, Y.-B. Xiang, W. Zheng, and X. O. Shu Polymorphisms in the CYP19A1 (Aromatase) Gene and Endometrial Cancer Risk in Chinese Women Cancer Epidemiol. Biomarkers Prev., May 1, 2007; 16(5): 943 - 949. [Abstract] [Full Text] [PDF]

				J. E. Olson, C. X. Ma, L. L. Pelleymounter, D. J. Schaid, V. S. Pankratz, R. A. Vierkant, Z. S. Fredericksen, J. N. Ingle, Y. Wu, F. Couch, et al. A Comprehensive Examination of CYP19 Variation and Breast Density Cancer Epidemiol. Biomarkers Prev., March 1, 2007; 16(3): 623 - 625. [Full Text] [PDF]

				S. H. Olson, E. V. Bandera, and I. Orlow Variants in Estrogen Biosynthesis Genes, Sex Steroid Hormone Levels, and Endometrial Cancer: A HuGE Review Am. J. Epidemiol., February 1, 2007; 165(3): 235 - 245. [Abstract] [Full Text] [PDF]

				A. J. Chien and P. E. Goss Aromatase Inhibitors and Bone Health in Women With Breast Cancer J. Clin. Oncol., November 20, 2006; 24(33): 5305 - 5312. [Full Text] [PDF]